GeneDx Holdings Corp. (WGS)
Automate Your Wheel Strategy on WGS
With Tiblio's Option Bot, you can configure your own wheel strategy including WGS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WGS
- Rev/Share 11.7288
- Book/Share 9.1447
- PB 9.9402
- Debt/Equity 0.4461
- CurrentRatio 3.2472
- ROIC -0.037
- MktCap 2593667880.0
- FreeCF/Share -0.4646
- PFCF -198.323
- PE -66.3275
- Debt/Assets 0.2572
- DivYield 0
- ROE -0.1712
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WGS | Guggenheim | -- | Buy | -- | $88 | May 15, 2025 |
| Upgrade | WGS | Jefferies | Hold | Buy | -- | $80 | May 9, 2025 |
| Initiation | WGS | Wells Fargo | -- | Equal Weight | -- | $34 | Aug. 28, 2024 |
News
Insiders Invested Millions in these Five Rebounding Stocks
Published: June 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Marriott Vacations Worldwide director Christian Asmar bought 412,449 shares for just over $27.88 million.
Read More
GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because of superior diagnostic yield and higher cost-effectiveness if pursued earlier in the diagnostic process2. For more.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: June 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
3 Medical Services Stocks Capitalizing on the Healthcare AI Boom
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS, BTSG and WGS are three medical services stocks tapping into AI and tech-driven care to boost diagnostics, cut costs and drive growth in 2025.
Read More
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced the publication of a new article demonstrating the company's leadership in applying AI to accelerate and enhance genetic diagnostics.
Read More
Best Momentum Stocks to Buy for May 5th
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
WGS, EBMT and CBNK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2025.
Read More
New Strong Buy Stocks for May 5th
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
WGS, NWG, HLF, CALM and ESEA have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2025.
Read More
GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2025 Earnings Conference Call April 30, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group Dan Brennan - TD Cowen Mark Massaro - BTIG Tycho Peterson - Jefferies Brandon Couillard - Wells Fargo Operator Good day, and thank you for standing by. Welcome to the GeneDx First Quarter 2025 Earnings Conference Call.
Read More
Why GeneDx Holdings Stock Is Plunging Today
Published: April 30, 2025 by: The Motley Fool
Sentiment: Negative
Shares of GeneDx Holdings (WGS -39.70%) were plunging 42.9% as of 11:21 a.m. ET on Wednesday.
Read More
GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.33 per share a year ago.
Read More
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the first quarter of 2025.
Read More
GeneDx: Strengthening Leadership In Genomic Diagnostics
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Positive
GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings. GeneDx will report Q1 2025 earnings on April 30, with expectations for continued revenue growth and margin improvement. Expanding market opportunity by leveraging data set expertise across more disease applications, new patient access channels, adult diagnostics, and international markets.
Read More
Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.
Read More
GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich
Published: March 12, 2025 by: Seeking Alpha
Sentiment: Positive
GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash, which makes me hesitant. At 7x sales, WGS stock feels expensive, given its current financials. If GeneDx can prove it can generate sustainable free cash flow, I'd reconsider my stance.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Reach Out
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS.
Read More
About GeneDx Holdings Corp. (WGS)
- IPO Date 2020-11-04
- Website http://www.genedx.com
- Industry Medical - Healthcare Information Services
- CEO Katherine A. Stueland
- Employees 1000